Literature DB >> 10940545

Analysis of risk taking in adults with a history of high risk behavior.

S D Lane1, D R Cherek.   

Abstract

Antisocial behavior often involves frequent risk-taking, e.g. excessive substance use and criminality, which may lead to destructive consequences. In the present study, adults with a history of high-risk behavior (primarily drug dependence and conduct disorder) and matched controls worked on a novel laboratory task designed to measure risk-taking. The contingencies of the task were such that choosing a 'risky' response option resulted in a net loss of monetary earnings compared to a safer, more conservative response alternative. The risky option offered a low probability of a large monetary reward or a high probability of a smaller monetary loss. The non-risky option protected current earnings. High-risk history subjects chose the risky option more often, had lower overall earnings, and were more likely to persist in making (losing) risky responses following a single gain on the risky option. The data support theories of maladaptive behavior focused on hypersensitivity to reward and insensitivity to aversive events.

Entities:  

Mesh:

Year:  2000        PMID: 10940545     DOI: 10.1016/s0376-8716(99)00155-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  21 in total

1.  Mesolimbic recruitment by nondrug rewards in detoxified alcoholics: effort anticipation, reward anticipation, and reward delivery.

Authors:  James M Bjork; Ashley R Smith; Gang Chen; Daniel W Hommer
Journal:  Hum Brain Mapp       Date:  2012-09       Impact factor: 5.038

2.  To drink or not to drink: Harmful drinking is associated with hyperactivation of reward areas rather than hypoactivation of control areas in men.

Authors:  Heiner Stuke; Stefan Gutwinski; Corinde E Wiers; Timo T Schmidt; Sonja Gröpper; Jenny Parnack; Christiane Gawron; Catherine Hindi Attar; Stephanie Spengler; Henrik Walter; Andreas Heinz; Felix Bermpohl
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

3.  The neurobiology of cognitive control in successful cocaine abstinence.

Authors:  Colm G Connolly; John J Foxe; Jay Nierenberg; Marina Shpaner; Hugh Garavan
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

4.  Cumulative gains enhance striatal response to reward opportunities in alcohol-dependent patients.

Authors:  Jodi M Gilman; Ashley R Smith; James M Bjork; Vijay A Ramchandani; Reza Momenan; Daniel W Hommer
Journal:  Addict Biol       Date:  2014-04-23       Impact factor: 4.280

Review 5.  Altered risk-related processing in substance users: imbalance of pain and gain.

Authors:  Joshua L Gowin; Scott Mackey; Martin P Paulus
Journal:  Drug Alcohol Depend       Date:  2013-04-23       Impact factor: 4.492

6.  Lorazepam dose-dependently decreases risk-taking related activation in limbic areas.

Authors:  Estibaliz Arce; Daniel A Miller; Justin S Feinstein; Murray B Stein; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

7.  Acute effects of alprazolam on risky decision making in humans.

Authors:  Scott D Lane; Oleg V Tcheremissine; Lori M Lieving; Sylvain Nouvion; Don R Cherek
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

8.  Striatal sensitivity to reward deliveries and omissions in substance dependent patients.

Authors:  James M Bjork; Ashley R Smith; Daniel W Hommer
Journal:  Neuroimage       Date:  2008-07-11       Impact factor: 6.556

9.  Diffusion tensor imaging and decision making in cocaine dependence.

Authors:  Scott D Lane; Joel L Steinberg; Liangsuo Ma; Khader M Hasan; Larry A Kramer; Edward A Zuniga; Ponnada A Narayana; Frederick Gerard Moeller
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

10.  Acquisition of Conditioned Responses to a Novel Alcohol-Paired Cue in Social Drinkers.

Authors:  Leah M Mayo; Harriet de Wit
Journal:  J Stud Alcohol Drugs       Date:  2016-03       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.